GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Hisoar Pharmaceutical Co Ltd (SZSE:002099) » Definitions » Equity-to-Asset

Zhejiang Hisoar Pharmaceutical Co (SZSE:002099) Equity-to-Asset : 0.72 (As of Sep. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Zhejiang Hisoar Pharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Zhejiang Hisoar Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was ¥5,467 Mil. Zhejiang Hisoar Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2024 was ¥7,610 Mil. Therefore, Zhejiang Hisoar Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.72.

The historical rank and industry rank for Zhejiang Hisoar Pharmaceutical Co's Equity-to-Asset or its related term are showing as below:

SZSE:002099' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.66   Med: 0.74   Max: 0.85
Current: 0.72

During the past 13 years, the highest Equity to Asset Ratio of Zhejiang Hisoar Pharmaceutical Co was 0.85. The lowest was 0.66. And the median was 0.74.

SZSE:002099's Equity-to-Asset is ranked better than
69.27% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs SZSE:002099: 0.72

Zhejiang Hisoar Pharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for Zhejiang Hisoar Pharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Hisoar Pharmaceutical Co Equity-to-Asset Chart

Zhejiang Hisoar Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.81 0.76 0.73 0.75

Zhejiang Hisoar Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.75 0.72 0.72 0.72

Competitive Comparison of Zhejiang Hisoar Pharmaceutical Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisoar Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Hisoar Pharmaceutical Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisoar Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Zhejiang Hisoar Pharmaceutical Co's Equity-to-Asset falls into.


;
;

Zhejiang Hisoar Pharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Zhejiang Hisoar Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=5606.352/7520.093
=0.75

Zhejiang Hisoar Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=5466.912/7609.931
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Hisoar Pharmaceutical Co  (SZSE:002099) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Zhejiang Hisoar Pharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Zhejiang Hisoar Pharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Hisoar Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 507 Shifu Avenue, Taizhou International Business Plaza, Block A, 8F, Taizhou, Zhejiang, CHN, 318000
Zhejiang Hisoar Pharmaceutical Co Ltd is a China-based company engages in the production of specialty raw materials, preparations and fine chemicals, dyes and dye intermediates. Its products include Clindamycin hydrochloride, Clindamycin phosphate, Florfenicol, Atova, Thiamphenicol, and Riglinay.
Executives
Wang Yang Chao Director
Yang Si Wei Directors, executives
Xu Guo Rui Executives
Xu Hua Qing Secretary Dong
Hong Ming Director
Guo Min Long Director
Li Hong Ming Executives
Jiang Ru Dong Securities Affairs Representative
Mao Wen Hua Executives
Sun Yang Director
Li Wei Jin Director
Luo Yu Hong Director
Pan Qing Hua Directors, executives
Chen Zheng Hua Supervisors
Jia Qiang Executives, directors

Zhejiang Hisoar Pharmaceutical Co Headlines

No Headlines